"Pyrimidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
| Descriptor ID |
D011743
|
| MeSH Number(s) |
D03.383.742
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrimidines".
Below are MeSH descriptors whose meaning is more specific than "Pyrimidines".
This graph shows the total number of publications written about "Pyrimidines" by people in this website by year, and whether "Pyrimidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 7 | 2 | 9 |
| 2003 | 13 | 5 | 18 |
| 2004 | 7 | 5 | 12 |
| 2005 | 2 | 7 | 9 |
| 2006 | 4 | 5 | 9 |
| 2007 | 13 | 1 | 14 |
| 2008 | 10 | 5 | 15 |
| 2009 | 7 | 6 | 13 |
| 2010 | 12 | 10 | 22 |
| 2011 | 16 | 2 | 18 |
| 2012 | 15 | 5 | 20 |
| 2013 | 9 | 8 | 17 |
| 2014 | 7 | 4 | 11 |
| 2015 | 3 | 5 | 8 |
| 2016 | 11 | 8 | 19 |
| 2017 | 7 | 5 | 12 |
| 2018 | 13 | 8 | 21 |
| 2019 | 6 | 4 | 10 |
| 2020 | 4 | 7 | 11 |
| 2021 | 8 | 13 | 21 |
| 2022 | 1 | 6 | 7 |
| 2023 | 0 | 9 | 9 |
| 2024 | 2 | 5 | 7 |
| 2025 | 3 | 3 | 6 |
| 2026 | 0 | 5 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrimidines" by people in Profiles.
-
UK SMA patient registry: a 3-year patient-reported outcome measures study supporting the drug appraisal of Nusinersen and Risdiplam in spinal muscular atrophy. J Neurol Sci. 2026 Nov 15; 490:126159.
-
Impact of Fostamatinib on Inflammatory Biomarkers in Hospitalized Patients With COVID-19. Crit Care Explor. 2026 Jul 01; 8(7):e1405.
-
Ruxolitinib and heart failure outcomes among patients with myelofibrosis. Leuk Lymphoma. 2026 May; 67(6):1335-1342.
-
Endogenous GIP signaling is indispensable for DPP-4 inhibitor-mediated metabolic control in mice. J Diabetes Investig. 2026 Apr; 17(4):567-575.
-
The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial. Clin Cancer Res. 2026 Jan 06; 32(1):148-158.
-
Clinical Significance of MTAP Deletions and Their Overlap With Concurrent Oncogenic Driver Alterations Including EGFR in NSCLC. J Thorac Oncol. 2026 03; 21(3):103520.
-
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial. Nat Med. 2025 Dec; 31(12):4281-4290.
-
Comparative Effectiveness of Tofacitinib vs Upadacitinib for the Treatment of Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2026 Mar; 24(3):784-793.
-
Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review. Target Oncol. 2025 Mar; 20(2):217-234.
-
Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study. Lung Cancer. 2025 04; 202:108417.